Toronto, ON – Genetic testing developer Tm Bioscience says it has signed a development and supply agreement with biotech company Genzyme. Together, the companies will develop, validate and implement a custom product that they say is expected to yield initial sales revenue in the first half of 2005. The specific nature of the collaboration was not disclosed.
“We look forward to working with Genzyme to commercialize innovations that bring significant clinical benefit to physicians and patients,” says Greg Hines, president and CEO of Tm Bioscience. “Genzyme’s adoption of our technology is a major milestone achievement and firmly establishes that our technology has the right stuff to attract the top players in our field.”